The Week

Merck (MRK) closed at $143.93, down 4.26% for the week, compared with a 0.8% pullback in the S&P 500 — an underperformance of about 3.46 percentage points. The decline took shape day by day: after opening higher on Tuesday at $148.41, the stock faded through Wednesday and Thursday and ended Friday just above its weekly low of $143.68. The 3.99% range and roughly in-line volume suggest a measured bout of profit-taking rather than a sharp sell-off.

Key Events

The week’s main company story was pipeline positioning ahead of the KEYTRUDA exclusivity window. On Sep 10, Merck said it was developing a roughly $70 billion pipeline to prepare for the loss of KEYTRUDA exclusivity. The same day, its M Ventures arm co-led a $62.5 million Series A for TwoStep Therapeutics. Earlier, Inhibrx reported mid-stage data showing INBRX-106 combined with pembrolizumab lifted the response rate to 48.3% in head and neck squamous cell carcinoma, adding another data point for KEYTRUDA combination use. By contrast, filings such as NewEdge Advisors adding 41,950 shares or Representative Salazar buying over $34k of stock carried limited informational weight.

Analyst Ratings

Across 28 institutions covering MRK, 15 rate it buy, 5 overweight and 8 hold, with no underweight or sell ratings. The consensus rating is buy, with a consensus target price of $152.96, roughly 6.3% above the last close of $143.93. The target range is wide — from $105 to $186 — signalling clear disagreement over the post-patent-cliff earnings path. Within the pharma sector, MRK ranks 3rd out of 206 companies by analyst rating.

The Week Ahead

On Sep 16, a batch of US retail and housing data lands: retail sales, retail sales ex-autos and the NAHB housing market index. Those prints will shape the read on consumer resilience. The next Merck-specific checkpoint is the Q3 FY2026 earnings release on Oct 29 pre-market, where estimates point to EPS of $1.90 and revenue of about $17.4 billion. Between now and then, any new KEYTRUDA combination trial data or licensing activity could shift the tone.

In Short

MRK’s pullback this week ran alongside the long-standing patent-cliff anxiety, but the sell-side panel remains tilted positive: 20 of 28 analysts rate it buy or overweight, and the consensus target sits above spot. The offset is valuation — about 112x trailing P/E and 8.5x book — and a trading premium that has widened relative to Lilly. The next test is whether late-October earnings can show pipeline contribution, and how retail data affects overall risk appetite.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.